KXAN

New TREMFYA® (guselkumab) Data Show an Overall Clinical Response Rate of Approximately 80 Percent in a Phase 2b Induction Study of Adults with Moderately to Severely Active ...

Previously reported results from QUASAR Induction Study 1 showed clinical response was achieved by approximately 60 percent of patients at week 12 Study results presented at 2022 American College of ...
MedPage Today

Guselkumab Shows Early Symptom Improvement in UC

Share on Facebook. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window New data from the QUASAR phase III induction study presented at ...
MedPage Today

New Guselkumab Responses in Ulcerative Colitis Emerge After 12 Weeks

In a previous video, investigator Jessica Allegretti, MD, of the Crohn's and Colitis Center at Brigham and Women's Hospital in Boston, discussed the results from the QUASAR phase III induction study ...
Healio

VIDEO: More than 75% of UC patients achieve clinical response at 24 weeks with Tremfya

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Tremfya bested placebo for achieved clinical response as ...
Nasdaq

Johnson & Johnson seeks U.S. FDA approval for subcutaneous induction regimen of TREMFYA® (guselkumab) in ulcerative colitis, a first for an IL-23 inhibitor

Following recent U.S. FDA approval of TREMFYA® for adults with moderately to severely active ulcerative colitis (UC), this submission underscores its potential to be the only IL-23 inhibitor that ...